If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
New Product Development » Early stage commercialization
Download FREE Excerpt
5 Info Graphics
10 Data Graphics
7 Best Practices
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
The investment decisions that drive product development cycles are exceedingly complex. Even during early-stage development, pharmaceutical companies and their portfolio management teams must balance scientific data with an awareness of what compounds hold the greatest potential market value.
Portfolio management is the linchpin in the precarious act of capital allocation during the early-stage commercialization process and throughout the lifecycle of a product. Portfolio management teams greatly impact the profitability of companies by determining the course of massive investments in R&D and by directing the volume and pace of funding for individual drug development projects.
Best Practices, LLC conducted this research to understand how well-aligned portfolio management teams incorporate both clinical and commercial insights into the early-stage commercialization process. This research also identifies the role played by various commercial functions on investment committees and the functional groups that most often lead investment committees for winning portfolio management teams.
Pharmaceutical executives involved with portfolio management and early commercialization activities can use this study to enhance portfolio decision-making capabilities and to promote functional alignment for early-stage investment decision groups.
NOTE: The data in this research are segmented into two parts: Large Pharma and Full Benchmark Class.
Pharmaceutical; Biotech; Manufacturing; Consumer Products; Diagnostic; Medical Device; Chemical; Health Care
Abbott Laboratories; Allergan; Alexion Pharmaceuticals; Altus Biologics; Amgen; AstraZeneca; Bayer; Eli Lilly & Co.; Genentech; GlaxoSmithKline; Human Genome Sciences; Intervet International (part of Schering-Plough); Merck; Neurocrine Biosciences; Novartis; Roche; Shire; Solvay Pharamaceuticals; Teva Pharmaceutical Industries; Vertex Pharmaceuticals